Insider Trading Alert - FLT, REGN And MXIM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 13, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,198.88 to $4,397,881,850,959.55.

Highlighted Stocks Traded by Insiders:

Fleetcor Technologies (FLT) - FREE Research Report

Stull Steven T who is Director at Fleetcor Technologies sold 26,255 shares at $115.00 on Feb. 13, 2014. Following this transaction, the Director owned 31,982 shares meaning that the stake was reduced by 45.08% with the 26,255-share transaction.

Coughlin John who is Exec VP, Corp Development at Fleetcor Technologies sold 17,575 shares at $115.84 on Feb. 13, 2014. Following this transaction, the Exec VP, Corp Development owned 27,230 shares meaning that the stake was reduced by 39.23% with the 17,575-share transaction.

The shares most recently traded at $116.87, up $1.03, or 0.88% since the insider transaction. Historical insider transactions for Fleetcor Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 4,910
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 109,910
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 2.9 million

The average volume for Fleetcor Technologies has been 1.0 million shares per day over the past 30 days. Fleetcor Technologies has a market cap of $9.6 billion and is part of the services sector and diversified services industry. Shares are down 0.55% year-to-date as of the close of trading on Thursday.

FleetCor Technologies, Inc. provides fuel cards and workforce payment products and services to businesses, commercial fleets, oil companies, petroleum marketers, and government entities in North America, Latin America, and Europe. The company has a P/E ratio of 28.7. Currently there are 2 analysts that rate Fleetcor Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLT - FREE

TheStreet Quant Ratings rates Fleetcor Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Fleetcor Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L who is Director at Regeneron Pharmaceuticals sold 1,000 shares at $320.62 on Feb. 13, 2014. Following this transaction, the Director owned 2,000 shares meaning that the stake was reduced by 33.33% with the 1,000-share transaction.

The shares most recently traded at $326.12, up $5.50, or 1.69% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 18,000

The average volume for Regeneron Pharmaceuticals has been 863,000 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $31.2 billion and is part of the health care sector and drugs industry. Shares are up 18.8% year-to-date as of the close of trading on Thursday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 39.2. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Maxim Integrated Products (MXIM) - FREE Research Report

Bergman James R who is Director at Maxim Integrated Products sold 2,000 shares at $30.67 on Feb. 13, 2014. Following this transaction, the Director owned 25,000 shares meaning that the stake was reduced by 7.41% with the 2,000-share transaction.

The shares most recently traded at $31.20, up $0.53, or 1.7% since the insider transaction. Historical insider transactions for Maxim Integrated Products go as follows:

  • 4-Week # shares sold: 24,475
  • 12-Week # shares sold: 29,475
  • 24-Week # shares sold: 57,121

The average volume for Maxim Integrated Products has been 3.2 million shares per day over the past 30 days. Maxim Integrated Products has a market cap of $8.6 billion and is part of the technology sector and electronics industry. Shares are up 9.82% year-to-date as of the close of trading on Thursday.

Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. The stock currently has a dividend yield of 3.39%. The company has a P/E ratio of 22.9. Currently there are 7 analysts that rate Maxim Integrated Products a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MXIM - FREE

TheStreet Quant Ratings rates Maxim Integrated Products as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Maxim Integrated Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

Market Recon: The Direction of Oil Has Been Somewhat Shocking

Market Recon: The Direction of Oil Has Been Somewhat Shocking

Energy Sector Down After the Energy Information Administration reported Oil Inventory Build-up

Energy Sector Down After the Energy Information Administration reported Oil Inventory Build-up

Diversity Measures on Corporate Boards Have a Breakout Year

Diversity Measures on Corporate Boards Have a Breakout Year

Trade-Ideas: Fleetcor Technologies (FLT) Is Today's Post-Market Leader Stock

Trade-Ideas: Fleetcor Technologies (FLT) Is Today's Post-Market Leader Stock